Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE)

NCT01632241 is registered in ClinicalTrials.gov with Human Genome Sciences Inc., a GSK Company as lead sponsor.

NCT NCT01632241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01632241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE)
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Phase
Phase 4
Overall status
Completed
Start date
February 19, 2013
Completion date
January 28, 2019
Enrollment
503 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus